title: Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients.
abstract: The effects of recombinant human erythropoietin (rHuEPO) on the glucose metabolism were evaluated by intravenous glucose tolerance test in 20 maintenance hemodialysis patients. In 8 cases the glucose tolerance tests were performed before and after a single intravenous injection of 50 IU/kg of rHuEPO and in 12 cases before and after 3 months of rHuEPO therapy at doses of 50 IU/kg three times/week and 2 weeks after rHuEPO withdrawal. For each test glucose, immunoreactive insulin (IRI) and C peptide (C-p) plasma values were measured, and glucose constant decay, whole IRI (area IRI) and C-p area C-p) production, insulinogenic index, and insulin resistance index were calculated. After 3 months of rHuEPO therapy, the glucose constant decay increased significantly, area IRI, area C-p, and insulin resistance index decreased significantly, and the insulinogenic index did not change. No correlations were found between changes in hemoglobin values and changes in glucose metabolism parameters. Acute rHuEPO administration and rHuEPO withdrawal had no effect on glucose metabolism, despite significant changes in plasma erythropoietin levels. Long-term rHuEPO therapy improves glucose metabolism in maintenance hemodialysis patients significantly, mainly by reduction of insulin resistance. Neither anemia correction nor a direct effect of rHuEPO on some metabolic steps seem to be responsible of these effects.
authors: Servizo Emodialisi, Ospedale di Palmanova, Regione Friuli-Venezia Giulia, Italia.
authors: V
authors: V
authors: Allegra
authors: G
authors: G
authors: Mengozzi
authors: L
authors: L
authors: Martimbianco
authors: A
authors: A
authors: Vasile
mesh_terms: D000328:Adult; D000368:Aged; D002096:C-Peptide / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D002096:C-Peptide; D007328:Insulin; D011994:Recombinant Proteins; D004921:Erythropoietin; D005947:Glucose